Evidence map›Paper›PMID 39333875›Full record

ArticleThe journal of headache and pain2024

First real-world study on the effectiveness and tolerability of rimegepant for acute migraine therapy in Chinese patients.

Zhao Yang, Xiaodan Wang, Mengyue Niu, Qiao Wei, Huizhu Zhong, Xiaoyan Li, Weihong Yuan, Wenli Xu, Shuo Zhu, Shengyuan Yu and 4 more

Registry-linked trialAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in The journal of headache and pain, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT05709106 (A Prospective Real World Study of Rimegepant in the Treatment of Migraine), which is not on this map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT05709106 completednot on this map

A Prospective Real World Study of Rimegepant in the Treatment of Migraine

TypeobservationalSponsorRuijin-Hainan Hospital Shanghai Jiao Tong University School Of MedicineRan2023 to 2025Enrolled173ConditionsMigraineArmsRimegepant 75 MG
3 · Its place in the literature

Who cites it

6 citing papers in PubMed.

  1. Article
  2. Observational
  3. Article
  4. Observational
  5. Review
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Zhao YangDepartment of Neurology, Institute of Neurology, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, No 197, Ruijin Second Road, Huangpu District, Shanghai, 20025, China.
Xiaodan WangDepartment of Neurology, Institute of Neurology, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, No 197, Ruijin Second Road, Huangpu District, Shanghai, 20025, China.
Mengyue NiuDepartment of Neurology, Institute of Neurology, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, No 197, Ruijin Second Road, Huangpu District, Shanghai, 20025, China.
Qiao WeiDepartment of Neurology, Hainan Branch, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, No 41, Kangxiang Road, Qionghai, 517434, China.
Huizhu ZhongDepartment of Neurology, Hainan Branch, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, No 41, Kangxiang Road, Qionghai, 517434, China.
Xiaoyan LiDepartment of Neurology, Hainan Branch, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, No 41, Kangxiang Road, Qionghai, 517434, China.
Weihong YuanHainan Lecheng Institute of Real World Study, Qionghai, China.
Wenli XuDepartment of Neurology, Institute of Neurology, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, No 197, Ruijin Second Road, Huangpu District, Shanghai, 20025, China.
Shuo ZhuDepartment of Neurology, Institute of Neurology, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, No 197, Ruijin Second Road, Huangpu District, Shanghai, 20025, China.
Shengyuan YuDepartment of Neurology, Chinese PLA General Hospital, Beijing, China.
Jun LiuDepartment of Neurology, Institute of Neurology, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, No 197, Ruijin Second Road, Huangpu District, Shanghai, 20025, China.
Jianzhou YanSchool of International Pharmaceutical Business, China Pharmaceutical University, Nanjing, China.
Wenyan KangDepartment of Neurology, Institute of Neurology, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, No 197, Ruijin Second Road, Huangpu District, Shanghai, 20025, China. kwymed22@163.com.
Peijian HuangDepartment of Neurology, Hainan Branch, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, No 41, Kangxiang Road, Qionghai, 517434, China. peijian1980@163.com.

Funding

Pfizer 88668477
6 · The paper itself

Abstract

backgroundRimegepant, a small molecule calcitonin gene-related peptide (CGRP) receptor antagonist, is indicated for acute and preventive migraine treatment in the United States and other countries. However, there is a lack of prospective real-world evidence for the use of rimegepant in Chinese migraine patients.

methodsThis was a single-arm, prospective, real-world study. While taking rimegepant to treat migraine attacks as needed, eligible participants were asked to record their pain intensity, functional ability, and accompanying symptoms for a single attack at predose and 0.5, 1, 2, 24, and 48 h postdose via a digital platform. Adverse events (AEs) during the rimegepant treatment period were recorded and analysed. The percentages of participants who experienced moderate to severe pain at predose and 0.5, 1, 2, 24, and 48 h postdose were assessed. Additionally, the percentages of participants who reported better/good outcomes in terms of pain intensity, functional ability, and accompanying symptoms at 0.5, 1, 2, 24, and 48 h postdose were analysed. In addition, the total cohort (full population, FP) was stratified into a prior nonresponder (PNR) group to observe the effectiveness and safety of rimegepant for relatively refractory migraine and a rimegepant and eptinezumab (RE) group to observe the effectiveness and safety of the combination of these drugs.

resultsBy November 24th, 2023, 133 participants (FP, n = 133; PNR group, n = 40; RE group, n = 28) were enrolled, and 99 participants (FP, n = 99; PNR group, n = 30; RE group, n = 23) were included in the analysis. Rimegepant was effective in treating migraine in the FP and both subgroups, with a significant decreasing trend in the percentages of participants experiencing moderate to severe pain postdose (p < 0.05) and a marked increase in the percentages of participants who reported better/good outcomes in terms of pain intensity, functional ability, and accompanying symptoms at 0.5, 1, 2, 24, and 48 h postdose compared with predose. AEs were reported by 6% of participants in the FP, and all AEs were mild.

conclusionsIn the real world, rimegepant is effective in the acute treatment of migraine patients in China. The low incidence rate of AEs highlighted the favourable tolerability profile of rimegepant.

trial registrationClinicaltrials.gov NCT05709106. Retrospectively registered on 2023-02-01.

Indexed as

Calcitonin Gene-Related Peptide Receptor AntagonistsMigraine DisordersPyridinesAdultChinaEast Asian PeopleFemaleHumansMaleMiddle AgedPiperidinesProspective StudiesTreatment OutcomeYoung AdultCalcitonin Gene-Related Peptide Receptor AntagonistsPiperidinesPyridinesrimegepant sulfateEffectivenessMigraineReal-worldRimegepantTolerability

Identifiers

PMID39333875
PMCPMC11438109

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.